The sections below cover how each one acts, what direct comparisons report on weight and blood sugar, how side effects line up, and what a clinician weighs before choosing.
They are prescription medicines that act on receptors for incretins, the hormones the gut releases after a meal to help the body handle food.
Incretins do several jobs at once. They prompt the pancreas to release insulin when blood glucose is rising, they slow the pace at which the stomach hands food on to the intestine, and they send signals to the appetite centres of the brain that register fullness. A medicine built to engage an incretin receptor borrows those signals and holds them in place for longer than the body's own short-lived hormones manage on their own.
A FitScript clinician, like any licensed prescriber, evaluates whether semaglutide, which acts at the GLP-1 receptor, or tirzepatide, which acts at both the GIP and GLP-1 receptors, is appropriate before writing a prescription.
That structural difference is the whole comparison in miniature. One medicine engages a single incretin receptor. The other engages two. The weight numbers, the blood sugar numbers and the side effect picture all sit downstream of that, with a person's biology, history and tolerance layered on top.
Research suggests that choosing between the two in practice is a clinical judgement balancing glucose goals, weight goals, tolerability and access rather than a simple ranking of one above the other 1.
Neither one replaces the rest of metabolic health work. Protein intake, resistance training, sleep and stress handling keep doing what they always did, and a licensed provider decides how a medicine sits alongside them rather than instead of them. How it is prescribed is decided by your clinician, not by an article.
The shared target is the GLP-1 receptor, and one of the two adds a second target, the GIP receptor.
GLP-1 is released from cells in the lower small intestine and colon in response to a meal. When it binds its receptor on the pancreas, insulin release is amplified, and because that amplification depends on glucose actually being elevated, the effect is largest after eating and small when glucose is sitting low. GLP-1 also slows gastric emptying, which spreads the glucose rise from a meal across a longer window, and it reaches receptors in brain regions that regulate appetite and food reward. What people describe is a meal that feels finished sooner and food thoughts that quieten between meals.
GIP is the other main incretin, released higher up in the small intestine. It also amplifies glucose-dependent insulin release, and it has activity at fat tissue, where it influences how incoming nutrients are taken up and stored. Engaging both receptors therefore acts on an overlapping but not identical set of tissues.
Research suggests that acting at both incretin receptors rather than one is the defining difference between the two medicines 2.
Two targets does not mean double the effect. Receptor biology is not additive in a tidy way, tissue responses differ from person to person, and how someone's digestive system reacts has as much to do with whether a medicine is workable for them as any receptor diagram does.
It matters because the two receptors sit on different tissues, so the second target changes the shape of the overall effect rather than simply amplifying the first.
The GIP receptor appears on pancreatic cells and on fat cells, which is why adding it is thought to influence both insulin secretion and the way fat tissue handles energy arriving from a meal. The GLP-1 receptor's strongest contributions are slowed stomach emptying and appetite signalling in the brain. Pulling two levers rather than one nudges the system in more places at once, and that can show up as a difference in average results and as a difference in how the medicine feels day to day.
Research suggests that acting at both receptors may help produce larger average weight reduction than acting at the GLP-1 receptor alone 2.
Average is the load-bearing word in that sentence. An average separates two groups; it does not describe the person reading this. Within either group there are people who respond strongly, people who respond modestly and people who stop because their stomach never settles. A person can do better on the single receptor medicine than on the dual receptor one, which is exactly why the decision belongs to a licensed provider who knows the individual rather than to a league table.
In adults with type 2 diabetes, research suggests that the dual receptor medicine produced greater average weight reduction than the single receptor medicine when the two were compared directly 3.
A direct comparison matters because both groups are drawn from the same population and followed the same way, so the comparison is not stitched together from separate sources with different participants and different lengths of follow-up.
Studies indicate that, in network comparisons of weight management in obesity, the dual receptor medicine ranked ahead of the single receptor medicine on weight outcomes 4.
Those findings describe group averages, not forecasts. Food environment, protein and fibre intake, training that protects lean mass, sleep, other prescriptions and simple consistency all move the result, and tolerance decides whether a medicine is continued at all.
A licensed provider reads these findings next to a person's own history, other conditions and tolerance when deciding whether semaglutide or tirzepatide is appropriate 1.
Studies indicate that the dual receptor medicine produced larger average reductions in Hemoglobin A1C than the single receptor medicine in adults with type 2 diabetes 5.
Hemoglobin A1C is the standard yardstick here because it reflects average blood glucose across roughly the prior two to three months rather than a single morning. Glucose attaches to hemoglobin inside red blood cells in proportion to how much is circulating, and red cells live long enough for that attachment to build into a running average.
There are plausible routes from an incretin medicine to a lower average. Insulin release is amplified when glucose is high, the slower handover of food from stomach to intestine flattens the peak that follows a meal. In people without diabetes, the same marker is read as a picture of where average glucose is sitting rather than as a management target.
Low blood sugar deserves a mention, since the glucose-lowering effect through this pathway depends on glucose being elevated. When other glucose-lowering prescriptions are already in play, the risk picture changes, which is one reason the prescriber reviews the entire medicine list rather than one item in isolation. Warning signs and who to call sit further down this page.
Digestive effects dominate the picture for both, and research suggests the reported effects include nausea, vomiting, diarrhoea and constipation 6.
Research suggests that, in people with obesity and without diabetes, both medicines were associated with more gastrointestinal adverse events than placebo 7.
Research suggests that differences in tolerability between the two are part of what shapes clinical decision-making in obesity management 6.
In plain terms, the side effect conversation is mainly a gut conversation, and it is personal. Some people settle into a medicine with little trouble. Some people find the stomach effects persist and decide, with the prescriber, that it is not the right fit. Because both medicines slow how quickly the stomach empties, the way a person eats interacts with how they feel, and what to adjust is worked out with the prescriber rather than guessed at.
Two rules make the rest of this simpler. Report anything new to the prescriber instead of stopping or altering a prescription alone, and keep the serious warning signs listed near the end of this page in their own category, because those are not a tolerance question.
Research suggests that both medicines were associated with weight reduction in people who had regained weight after bariatric surgery 8.
That situation comes up more than people expect. Surgery changes the anatomy and the hormonal signalling around eating, and for some people weight returns over the years that follow. The question of what to do next is a clinical one, handled by the surgical and medical team together, and a licensed provider decides whether an incretin medicine belongs in that plan at all.
Beyond weight and glucose, research suggests that weight reduction with these medicines may help with weight-related conditions 2.
Research suggests that effects reaching past body weight, including on obesity-related disease and on consumption behaviours, have been described for both medicines 9.
Take those two sentences for exactly what they say and no further.
The decision belongs to a licensed provider, and it rests on far more than which medicine performed better on average.
The inputs a prescriber works through generally include the following:
Research suggests that weighing these factors together, rather than ranking the medicines in the abstract, is what clinical decision-making in this class looks like 1.
If weight is the reason for the question, a conversation with a FitScript clinician about medical weight loss for men or medical weight loss for women is where a comparison turns into a decision, because a licensed provider evaluates whether either medicine is appropriate and how it is prescribed is decided by that clinician.
Hemoglobin A1C is the marker that tracks average blood glucose across roughly the prior two to three months, which makes it the main lab people watch alongside this conversation.
| Hemoglobin A1C | Range | How to read it |
|---|---|---|
| FitScript optimal range | 4.6 to 5.3 % | FitScript's optimization target, not a diagnostic cut-off |
| Your lab's own reference range | As printed on your lab report | Reference ranges vary by lab, age and sex |
FitScript's optimal range is an optimization target rather than a diagnostic threshold, and the range printed beside your result on the report is the one your laboratory applies to its own method. Reference ranges vary by lab, age and sex, so two reports can describe the same number differently.
The useful way to read any single value is in three steps. The observation is what the number says about average glucose over the measurement window. The meaning is a hypothesis, not a verdict, since several things other than glucose can move the result. The next step is a conversation with a clinician who can put the value next to the rest of the panel, the symptoms and the history. A value outside the range printed on your report is an observation worth discussing, never something to set aside.
A higher result reflects more glucose circulating on average across the measurement window, and a lower result reflects less, with several caveats that matter in both directions.
On the higher side, the value may reflect insulin resistance building quietly, a pattern of eating that concentrates refined carbohydrate, poor sleep, a stretch of low activity, ongoing stress, recent illness, or a condition a clinician evaluates directly. What a single higher value does not do is name a diagnosis. It flags a trend worth checking, ideally against fasting glucose and fasting insulin from the same draw.
On the lower side, the number can reflect genuinely lower average glucose, and it can also read low for reasons that have nothing to do with glucose. Conditions that shorten the lifespan of red blood cells give the glucose less time to attach, so the average reads lower than the body is actually running. That is why a complete blood count sitting next to an A1C is worth more than an A1C alone.
A suboptimal value in either direction is information, not a verdict. What makes it useful is the repeat measure, the markers beside it and a clinician's read of the whole picture.
Several things unrelated to day to day eating can move this number, which is why it is read alongside other markers rather than on its own.
Red blood cell turnover is the big one. Anything that shortens or lengthens the life of red cells changes how much glucose has had the chance to attach, so iron status, blood counts and certain inherited hemoglobin variants all influence the result. Kidney function matters for the same reason, through its effect on red cell production and survival. Laboratory method differences play a smaller part, which is one argument for keeping repeat testing within the same laboratory when possible.
Pregnancy changes both glucose physiology and red cell turnover, and glucose targets in pregnancy are handled differently, so that is a question for your OB or midwife. Age shifts the interpretation gently rather than the biology. Recent acute illness can nudge glucose for weeks without saying anything durable about metabolic health.
The practical takeaway is that this marker is excellent at describing an average and poor at describing a week. A sharp change in eating or training will not appear in full for a couple of months, and a value that moves sharply without any matching change in behaviour is worth asking a clinician about rather than explaining away.
It is measured on a standard blood sample, and fasting is not required for this particular marker.
Other markers drawn at the same visit, fasting glucose and fasting insulin among them, do require an overnight fast, so the practical answer is to follow the fasting instructions given for the whole draw rather than for one marker. Results come back as a percentage, with the laboratory's own reference range printed beside the value.
The interval between tests is decided with a clinician, and the biology sets a floor on how soon a repeat makes sense. Because the value reflects two to three months of average glucose, re-checking a few weeks after a change shows a partial picture at best. People who are following a change in eating, training or a prescription are generally reviewed on a cadence their clinician sets, with fasting glucose and fasting insulin filling in the shorter-term detail that an average cannot show.
One more practical point. Keep the reports. A single value answers almost nothing a trend can answer, and the direction of travel across three or four draws is what a clinician can actually work with.
The markers that earn their place beside this one either describe glucose handling from another angle or explain why the average itself might mislead.
Fasting glucose shows where the system sits after an overnight rest, and fasting insulin shows how hard the pancreas is working to hold it there, which is information an average glucose marker cannot provide. A lipid panel, with triglycerides and HDL read together, describes how the metabolic picture is affecting circulating fats. Liver markers matter because the liver is central to glucose storage and release, and because fat accumulation in the liver travels with insulin resistance. Kidney markers matter both in their own right and because kidney function shapes red cell survival. A complete blood count, including the red cell indices, is the check on whether the average is trustworthy in the first place. Thyroid markers round out the metabolic context.
FitScript's membership covers 150+ biomarkers tested per year, and Atlas, FitScript's AI health advisor, writes the interpretation from a member's own biology. A licensed clinician reviews the results and decides what they mean and what to do next.
One place a reader can look at this marker alongside other metabolic measures is the Metabolic + Insulin panel. The same marker also appears in the Metabolic & Longevity Add-On, GLP-1 Monitoring, the Longevity / Peptide Panel, FitScript Essential, Baseline + Hormones, the Hormone Panel for men and the Hormone Panel for women, and FitScript Complete for men and FitScript Complete for women. A licensed clinician reviews the results and decides what they mean and what to do next.
Anything in the first group below is an emergency, not a question for the next appointment.
Outside those situations, a few things are worth raising at a scheduled review. A result outside the range printed on your lab report is worth discussing with a clinician promptly, as is a value that moves sharply with no matching change in behaviour. Pregnancy, breastfeeding or plans to conceive belong in the conversation with your OB or midwife and the prescriber, early rather than late. So does any new prescription from another clinician, because glucose-lowering effects can stack.
This page is educational and is not medical advice. Discuss your own results and any treatment decision with a clinician or licensed provider, who decides what is appropriate for you. FitScript publishes this comparison for education and is not affiliated with or endorsed by any medicine manufacturer.
More FitScript reading on this topic: a plain explanation of what a GLP-1 is, a guide to GLP-1 side effects, and a further comparison of GLP-1 options.
One acts at the GLP-1 receptor and the other acts at both the GIP and GLP-1 receptors, which is the structural difference behind everything else people compare. A licensed provider evaluates whether semaglutide or tirzepatide is appropriate for a given person. The receptor diagram is the starting point of that conversation, not the conclusion.
There is no answer that applies to everyone. What happens for one person depends on tolerance, other diagnoses, consistency with food and training, sleep, and what else they are already prescribed. A licensed provider decides which medicine, if either, is appropriate after reviewing the full picture.
Yes. Both are prescription medicines, so a licensed clinician reviews a person's history, labs and goals and decides whether semaglutide or tirzepatide is appropriate. How it is prescribed is decided by that clinician, and nothing about it should be sourced outside a licensed prescriber.
That decision belongs to a licensed prescriber, who looks at why the change is being considered, how the first one was tolerated and what the current labs show. Do not change anything independently. Bring the question to the prescriber before the next review rather than after.
Hemoglobin A1C sits at the centre, with fasting glucose and fasting insulin beside it to describe the shorter-term picture. A lipid panel, liver and kidney markers and a complete blood count add the context that explains whether the average is trustworthy. A licensed clinician reviews the results and decides what they mean and what to do next.
Not on its own. The value is an average across roughly two to three months, so it can smooth over swings within a day, and conditions that change red blood cell turnover can pull it up or down independently of glucose. Read it next to fasting glucose, fasting insulin and how you actually feel, with a clinician.
Tell the prescriber about any new symptom that does not settle, especially anything involving the stomach or gut or anything that makes eating and drinking hard. Severe abdominal pain that does not go away, or vomiting or diarrhoea with no fluids kept down, means calling 911 or going to the emergency department. Low blood sugar with confusion, fainting, a seizure, or being unable to eat or drink means calling 911. Shakiness or sweating with low blood sugar is a reason to contact the prescriber the same day.